Polyclonal Antibody to Corticotropin Releasing Hormone Binding Protein (CRHBP)
| Code | Size | Price |
|---|
| PAC401Ra01-20ul | 20ul | £92.00 |
Quantity:
| PAC401Ra01-100ul | 100ul | £173.00 |
Quantity:
| PAC401Ra01-200ul | 200ul | £234.00 |
Quantity:
| PAC401Ra01-1ml | 1ml | £539.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CRF-BP; CRFBP; Corticotropin-Releasing Factor-Binding Protein
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Corticotropin Releasing Hormone Binding Protein
Reactivity:
Mu;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/ml<br/>Immunocytochemistry in formalin fixed cells: 5-20ug/ml<br/>Immunohistochemistry in formalin fixed frozen section: 5-20ug/ml<br/>Immunohistochemistry in paraffin section: 5-20ug/ml<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Corticotropin Releasing Hormone Binding Protein (CRHBP) | RPC401Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||